Skip to content

Study · Randomized controlled trial · n = 407 · 2016

3 results

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.

Bailey TS, Takács R, Tinahones FJ, Rao PV, Tsoukas GM, Thomsen AB, Kaltoft MS, Maislos M

Diabetes, obesity & metabolism14 Sept 2016Cited by 30 (Europe PMC)

PMID27381275 (opens in a new tab)PMCIDPMC5129465 (opens in a new tab)DOI10.1111/dom.12736 (opens in a new tab)PepBankPUB-27381275
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes inadequately controlled on sitagliptin and metformin, switching to liraglutide lowered HbA1c more than continuing sitagliptin.

    In plain wordsIn adults with type 2 diabetes, switching from sitagliptin to liraglutide lowered HbA1c more than staying on sitagliptin.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change from baseline to week 26
    Study

    n = 407

    Comparator
    Continued sitagliptin plus metformin
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.14%
    liraglutide
    HbA1c change
    −0.54%
    sitagliptin
    Estimated treatment difference
    −0.61%
    liraglutide vs sitagliptin

    Source sentences

    Summary
    Greater reduction in mean HbA1c was achieved with liraglutide than with continued sitagliptin [-1.14% vs. -0.54%; estimated mean treatment difference (ETD): -0.61% (95% CI -0.82 to -0.40; p < 0.0001)], confirming superiority of switching to liraglutide.
    1 context sentence
    Summary · context
    Subjects with type 2 diabetes who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100 mg/d) and metformin (≥1500 mg daily) for ≥90 days were randomized to either switch to liraglutide (n = 203) or continue sitagliptin (n = 204), both with metformin.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes inadequately controlled on sitagliptin and metformin, body weight fell more after switching to liraglutide than with continued sitagliptin.

    In plain wordsIn adults with type 2 diabetes, weight fell more after switching to liraglutide than with continued sitagliptin.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 407

    Comparator
    Continued sitagliptin plus metformin
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Measurements

    Body weight change
    −3.31 kg
    liraglutide
    Body weight change
    −1.64 kg
    sitagliptin
    Estimated treatment difference
    −1.67 kg
    liraglutide vs sitagliptin

    Source sentences

    Summary
    Body weight was reduced more with liraglutide [-3.31 kg vs. -1.64 kg; ETD: -1.67 kg (95% CI -2.34 to -0.99; p < 0.0001)].
    1 context sentence
    Summary · context
    Subjects with type 2 diabetes who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100 mg/d) and metformin (≥1500 mg daily) for ≥90 days were randomized to either switch to liraglutide (n = 203) or continue sitagliptin (n = 204), both with metformin.
  3. 03HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, nausea was more common after switching to liraglutide than with continued sitagliptin.

    In plain wordsIn adults with type 2 diabetes, nausea was more common with liraglutide than with sitagliptin.

    Peptide
    Liraglutide
    Outcome
    IncreaseNausea
    Study

    n = 407

    Comparator
    Continued sitagliptin plus metformin
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.8 mg/d · 26 weeksAs given in this study (human).

    Measurements

    Nausea
    21.8%
    liraglutide
    Nausea
    7.8%
    sitagliptin

    Source sentences

    Summary
    Nausea was more common with liraglutide [44 subjects (21.8%)] than with continued sitagliptin [16 (7.8%)].
    1 context sentence
    Summary · context
    Subjects with type 2 diabetes who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100 mg/d) and metformin (≥1500 mg daily) for ≥90 days were randomized to either switch to liraglutide (n = 203) or continue sitagliptin (n = 204), both with metformin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01907854

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

Novo Nordisk A/Sn = 4072 Dec 2013 to 15 Jun 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 2 Oct 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.